Second Genome, Inc.: Series A $5M

Posted in I - Series A, Q - 3Q11, R - WEST, X - CRO, X - Device (Diagnostic), X - Target ID, XX - CA

Second Genome (San Francisco, CA) a commercial-stage microbial profiling company designed to enable diagnostic/prognostic signatures and target identification, closed a $5M Series A financing. Participants include Advanced Technology Ventures, Morgenthaler Ventures, Wavepoint Ventures and Seraph Group.
Thanx for your patience as we catch-up.

Jan

2009

FORMA Therapeutics, Inc.: Series A $25M

Posted in I - Series A, Q - 1Q09, R - NORTH EAST, X - Oncology, X - Target ID, X - Therapeutic Platform, XX - MA

FORMA Therapeutics (Cambridge, MA) an oncology focused target discovery, screening, structural biology and small molecule developer, closed a $25M Series A funding financing. Participants include Novartis Option Fund and Bio*One Capital.

Dec

2008

Biomics Biotechnologies, Inc.: Series B $5M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - RNAi, X - Target ID

Biomics Biotechnologies (China) development-stage company focused on target identification and RNAi therapeutics, closed a $5M Series B financing. Participants include Jiangsu Dinghong Venture Capital and Jiangsu Benefit Rise Group.

Nov

2008

Evolutionary Genomics: Series A $3M

Posted in I - Series A, Q - 2Q08, R - ROCKY MOUNTAIN, X - Bioagriculture, X - Target ID

Evolutionary Genomics (Lafayette, CO), a commercial-stage agricultural technology company with a proprietary gene discovery platform, closed a $3.0M Series A financing. Participants include Altira Group.

to top of page...